Cannabidiol (CBD) in Adults With ASD
Crossover Trial of Cannabidiol (CBD) Versus Placebo for Psychiatric Presentations in Adults With Autism Spectrum Disorder
Johns Hopkins University
40 participants
Apr 20, 2023
INTERVENTIONAL
Conditions
Summary
There are no FDA approved treatments for use in adults with autism spectrum disorder (ASD), many of whom have distressing anxiety, mood disturbances, sleep problems, and agitation. Some researchers and individuals with ASD have noted that cannabidiol (CBD) is beneficial for those psychiatric problems. This study is to learn more about the effectiveness and safety of CBD in the treatment of psychiatric problems in adults with ASD. The study will last 14 weeks total, during which six weeks participants will receive a pill containing CBD, two weeks where participants will receive no drug/placebo, and six weeks where participants will receive the placebo, an inactive pill. As part of the study, participants will have regular visits and be asked questions about anxiety, challenging behaviors, daily functioning, cognition, and physical symptoms, on standard assessments.
Eligibility
Inclusion Criteria2
- ASD based on Diagnostic Statistical Manual 5 (DSM-5) criteria
- a significant mood disorder, sleep disturbance, or exhibit agitation, aggression, or other aberrant behavior that is interfering with function and quality of life, as determined by their psychiatric interview
Exclusion Criteria5
- history of alcohol or substance use disorder
- positive urine tetrahydrocannabinol screen at onset of study
- individuals who are pregnant, lactating, or planning pregnancy during or within three months of completing the trial
- individuals with unstable liver disease
- individuals taking medications where CBD interaction might significantly alter drug levels, such as clobazam
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The study intervention will be supplied as a softgel capsule containing cannabidiol.
The study intervention will be supplied as a softgel capsule containing inert filler.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05015439